Benzene Ring Containing Patents (Class 514/764)
  • Patent number: 11298358
    Abstract: An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly a cancer. The present invention provides a combination therapy using a compound presented by formula (I), a pharmaceutically acceptable salt or a solvate thereof with an immune checkpoint inhibitor.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 12, 2022
    Inventor: Tatsuo Hoshino
  • Publication number: 20150147288
    Abstract: The invention generally relates to environmental friendly pesticide compounds, formulations, methods of preparation and application and utilities thereof. More particularly, the invention relates to pesticide compounds and formulations that include terpenes or terpenoids having chemical formula of (C5H8)n, and its derivatives and analogs thereof, as active insecticidal ingredients; certain botanical essential oils as synergists, and other select ingredients as additives.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Inventor: Tao Zhong
  • Patent number: 8999399
    Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.
    Type: Grant
    Filed: November 14, 2009
    Date of Patent: April 7, 2015
    Assignee: Bose Chemie GmbH
    Inventors: Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
  • Patent number: 9000050
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: April 7, 2015
    Assignee: The University of British Columbia
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Patent number: 8980954
    Abstract: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: March 17, 2015
    Assignee: STC.UNM
    Inventors: David L. Vander Jagt, Lorraine M. Deck
  • Patent number: 8933132
    Abstract: The invention relates to novel piperazine compounds of formula (I): to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: January 13, 2015
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: David Norton, Daniele Andreotti, Simon E. Ward, Roberto Profeta, Simone Spada, Helen Susanne Price
  • Publication number: 20140323413
    Abstract: Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.
    Type: Application
    Filed: March 15, 2012
    Publication date: October 30, 2014
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Gregory Hageman, Yingbin Fu
  • Patent number: 8822489
    Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: September 2, 2014
    Assignee: Acura Pharmaceuticals
    Inventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
  • Patent number: 8715704
    Abstract: The invention relates to a lure for attracting, and in some circumstances, killing dust mites, especially house dust mites. The lure comprises neryl formate and/or limonene and is usually arranged in powder form to allow it to be shaken over an area containing the mites. What about liquid that dries.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: May 6, 2014
    Assignees: London School of Hygiene & Tropical Medicine, Rothamsted Research Limited
    Inventors: Amanda Skelton, Mary Cameron, Michael Alexander Birkett, John Anthony Pickett
  • Patent number: 8703161
    Abstract: Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: April 22, 2014
    Assignee: ELC Management, LLC
    Inventors: Daniel H. Maes, Nadine A. Pernodet, Thomas Mammone, Edward Pelle, Donald F. Collins, Lenny Slutsky, Kerri Goldgraben
  • Patent number: 8691253
    Abstract: The invention relates to a method of use, of a mixture of chemical compounds for a shark repellent, as well as methods of protection garments in using such material(s). Generally, there are not many shark repellents. This shark repellent contains a mixture of chemical compounds that are highly toxic and trenchant, which will deter the shark from injured or non-injured humans or animals, once the mixture is immersed in water.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: April 8, 2014
    Inventor: Rhonda Tracy
  • Patent number: 8648118
    Abstract: This invention relates to bicyclic ring system substituted amide functionalized phenols of general formula 1, their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: February 11, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Dieter Hamprecht, Barbara Kistler, Iain Lingard
  • Publication number: 20130331462
    Abstract: The present invention provides natural and/or simulated, synthetic, synergistic pesticidal compositions comprising terpenes, such as extracts from Chenopodium ambrosioides near ambrosioides, or compositions based on those found in Chenopodium ambrosioides near ambrosioides. The present invention also provides methods of using said compositions to kill, inhibit, prevent and/or repel plant pests from contacting and/or damaging plants.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 12, 2013
    Applicant: Bayer CropScience LP
    Inventors: Desmond JIMENEZ, Giselle JANSSEN, Dennis LONG, Brett HIGHLAND, Tara LU, Gerardo BUENO
  • Patent number: 8551489
    Abstract: Methods for the treatment of cancers involving dysregulation of thromboxane receptor ? (TP-?) are provided, including in certain aspects methods for diagnosing such cancers. Specific cancers included are genitourinary cancers, gastrointestinal cancers and leukemias.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: October 8, 2013
    Assignee: MUSC Foundation for Research Development
    Inventors: Omar Moussa, Dennis K. Watson, Perry V. Halushka
  • Patent number: 8507013
    Abstract: The present invention comprises compositions, methods and cell lines related to controlling insects. An embodiment of a composition comprises a plant essential oil and targets at least one receptor of insects chosen from tyramine receptor, Or83b olfactory receptor, and Or43a olfactory receptor, resulting in a change in the intracellular levels of cAMP, Ca2+, or both in the insects.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: August 13, 2013
    Assignee: TyraTech, Inc.
    Inventor: Essam Enan
  • Patent number: 8461212
    Abstract: The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like).
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: June 11, 2013
    Assignee: GENFIT
    Inventors: Jamila Najib, Karine Caumont-Bertrand
  • Patent number: 8445544
    Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: May 21, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Peter Turecek, Juergen Siekmann
  • Patent number: 8440648
    Abstract: The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: May 14, 2013
    Assignees: Erimos Pharmaceuticals LLC, University of Maryland, Baltimore, Johns Hopkins University
    Inventors: Neil Frazer, Jonathan Heller, Rocio Lopez, Melissa Rhodes, Ru Chih C. Huang, Richard Dalby, Niharika Khanna
  • Patent number: 8426473
    Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: April 23, 2013
    Assignee: High Point Pharnaceuticals, LLC
    Inventor: Soren Ebdrup
  • Publication number: 20130053451
    Abstract: Suggested are biocide compositions, comprising (a) at least one dialkylamide based on a hydroxycarboxylic acid, and (b) at least one biocide. The compositions exhibit an improved stability even if stored at temperatures between 5° and 40° C. over a longer period.
    Type: Application
    Filed: October 19, 2012
    Publication date: February 28, 2013
    Applicant: Cognis IP Management GmbH
    Inventor: Cognis IP Management GmbH
  • Patent number: 8367735
    Abstract: The present invention relates to compounds of formula I or II:—wherein R is an alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group, that may be substituted or unsubstituted, and that optionally includes at least one heteroatom in its carbon skeleton; R1 is hydrogen, or an alkyl, substituted alkyl, alkenyl, alkynyl, aryl, substituted aryl, or aralkyl group; and R2 is an alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group containing 4-12 carbon atoms, that may be substituted or unsubstituted, and that optionally includes at least one heteroatom in its carbon skeleton; provided that in a compound of formula I, when R1 is an iso-propyl or phenyl group, R2 is not an acetyl or tert-butyldimethylsilyl group; and their use in therapeutic, diagnostic and research methods.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: February 5, 2013
    Assignee: Crawford Healthcare Holdings Limited
    Inventors: Stanley M. Roberts, Gabriella M. Santoro
  • Publication number: 20130029922
    Abstract: The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 31, 2013
    Applicant: ORGANOMED CORPORATION
    Inventor: James N. Jacob
  • Patent number: 8349902
    Abstract: The invention relates to pharmacology, medicine and oncology, in particular, to a class of chemical compounds, the structure of which corresponds to formula (I) and which can be used in pharmaceutical compositions for preventing and treating an extended range of oncological diseases, including, in the form of an anti-tumoral preparation and a preparation which is used for combined therapy of oncological diseases.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: January 8, 2013
    Assignee: Mitotech SA
    Inventors: Vladimir P. Skulachev, Maxim V. Skulachev
  • Patent number: 8309612
    Abstract: An object of the present invention is to find a novel medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent inhibitory effect on neovascularization in the choroid and also has a protective effect on retinal pigment epithelial cell damage, and therefore is useful as a prophylactic or therapeutic agent for age-related macular degeneration.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: November 13, 2012
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Shin-ichiro Hirai, Atsushi Yoshida
  • Patent number: 8268895
    Abstract: The present invention concerns the use as perfuming ingredient, for instance to impart odor notes of the floral and/or green type, of a compound of formula 5 wherein R is an ortho, meta or para substituent of the phenyl, and represents a hydrogen atom or a C 1-2 alkyl or alkoxyl group; R 1 represents a hydrogen atom or a methyl or ethyl group; 10 R 2 represents a hydrogen atom or a C 1-3 alkyl group; and X represents a CHO, COOR 3, CH(OR 4) 2 or CN group, R 3 being a methyl or ethyl group, and R 4, taken seperately, being a methyl or ethyl group, or said R 4, taken together, a C 2-5 alkanediyl group; and at least one of said R, R 1 or R 2 represents a group containing at least one carbon atom.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: September 18, 2012
    Assignee: Firmenich SA
    Inventor: Robert Moretti
  • Patent number: 8217086
    Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: July 10, 2012
    Assignee: High Point Pharmaceuticals, LLC
    Inventor: Soren Ebdrup
  • Patent number: 8211454
    Abstract: A paper product having an antimicrobial composition dispersed with the substrate is provided. In particular, a paper towel such as those found in public washrooms or institutions comprises an antimicrobial composition. The substrate can also be a facial tissue, kitchen towel, serviette or any type of personal hygiene product. The antimicrobial composition preferably comprises a phenol-derived antimicrobial agent. The paper products of the present invention appear dry to the touch.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: July 3, 2012
    Assignee: Kruger Products L.P.
    Inventor: Philip Buder
  • Patent number: 8188152
    Abstract: Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryi optionally substituted with one or more groups R6; R2 is alkyl or is part of a ring with R3; R3 is H, alkyl or CH2 (when forming part of a ring with R2); R4 is H or alkyl or is part of a ring with R 5; R5 is aryl or heteroaryi optionally substituted with R7; each R6 is independently alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2alkyl, CONH2, SOMe, SO2NH2, Salkyl, CH2SO2alkyl or OCONalkyl2; R7 is R8 or (CH2)nOR8, R9, CF3, OH, OR9, OCOR9, COR9, COOR9, CONH2, CH2CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHCONHR7, NHCON(R9)2, NHCOR9, NHCOaryl, NHSO2Me, CONH2, SMe, SOMe or SO2NH2; R8 is (CH2)nOR9, (CH)nOR9, (CH2)nCOOR9 or (CH2)nCOaryl; R9 is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: May 29, 2012
    Assignee: Biocopea Limited
    Inventors: Robin Mark Bannister, Michael Harvey Lyne
  • Publication number: 20120107415
    Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.
    Type: Application
    Filed: November 14, 2009
    Publication date: May 3, 2012
    Inventors: Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
  • Publication number: 20120108675
    Abstract: The invention relates to a process and an apparatus for producing hydrocarbon components in the presence of a hydrodesulphurization catalyst. The components obtained by the process are suitable for use as fuel composition as such or as an additive in fuel compositions, and in cosmetics or pharmaceutical products.
    Type: Application
    Filed: July 2, 2010
    Publication date: May 3, 2012
    Applicant: UPM-KYMMENE CORPORATION
    Inventors: Pekka Knuuttila, Jaakko Nousiainen
  • Publication number: 20120095388
    Abstract: A method includes positioning an effective amount of a thermal target material at a treatment site of a patient. The treatment site, that is, the location of the thermal target material, comprises a location adjacent to biological tissue to be treated. The thermal target material includes carbon molecules preferably in a carrier fluid. Regardless of the particular structure of the carbon, the carbon molecules in the material heat very rapidly in response to incident microwave radiation and radiate heat energy. The heat energy radiated from an effective amount of the thermal target material when subjected to an effective quantity of microwave energy causes localized heating around the thermal target material. This localized heating may be applied for therapeutic purposes. However, the microwave radiation necessary to produce therapeutically effective heating is insufficient to cause cellular damage in the biological tissue by direct absorption in the tissue.
    Type: Application
    Filed: December 5, 2011
    Publication date: April 19, 2012
    Inventors: Anthony S. Wagner, Mark DeSantis
  • Patent number: 8158685
    Abstract: The present invention relates to novel chemical compositions and methods of treating and regenerating bone in a patient in need thereof. This invention presents a novel chemical composition of matter that stimulates osteoblast formation and inhibits osteoclastic and phagocytosis activity thereby resulting in a significant increase in bone formation.
    Type: Grant
    Filed: June 25, 2005
    Date of Patent: April 17, 2012
    Inventor: Gregory Gene Steiner
  • Publication number: 20120087889
    Abstract: The invention provides a method for controlling whiteflies which comprises the steps of: providing a composition comprising or consisting of R-curcumene and optionally further beta-myrcene, para-cymene, gamma-terpinene, alpha-terpinene, alpha-phellandrene zingiberene and/or 7-epi-zingiberene; and adding said composition one or more times to a plurality of crop plants. The method can be combined with the use of attractant compositions comprising beta-phellandrene, limonene and/or 2-carene, and optionally adding said composition one or more times to one or more trap plants and/or trap materials.
    Type: Application
    Filed: March 4, 2010
    Publication date: April 12, 2012
    Applicant: KEYGENE N.V.
    Inventors: Petronella Martina Bleeker, Kai Ament, Paul Johan Diergaarde, Michiel Theodoor Jan de Both, Robert Cornelis Schuurink
  • Publication number: 20120076751
    Abstract: The present invention provides compounds and compositions for attracting or repelling sap-sucking insects, such as whitefly, as well as methods for using such compositions.
    Type: Application
    Filed: September 25, 2008
    Publication date: March 29, 2012
    Inventors: Petronella Martina Bleeker, Kai Ament, Paul Johan Diergaarde, Michiel Theodoor Jan De Both, Robert Cornelis Schuurink
  • Patent number: 8128950
    Abstract: A paper product having an antimicrobial composition dispersed with the substrate is provided. In particular, a paper towel such as those found in public washrooms or institutions comprises an antimicrobial composition. The substrate can also be a facial tissue, kitchen towel, serviette or any type of personal hygeine product. The antimicrobial composition preferably comprises a phenol-derived antimicrobial agent. The paper products of the present invention appear dry to the touch.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: March 6, 2012
    Assignee: Kruger Products L.P.
    Inventor: Philip Buder
  • Patent number: 8129434
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: March 6, 2012
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Kun Peng, Lili Zhang, Binhua Lv, Baihua Xu, Jiajia Dong, Jiyan Du, Yan Feng, Ge Xu, Vasanthakumar Rajappan, Brian Seed
  • Publication number: 20120039796
    Abstract: A bio compatible free radical suspension, comprising of oxygen and electronically modified reaction intermediates, where a fluorocarbon is used as an inert medium for stabilization of reaction intermediates. A stabilized bio compatible electronically modified derivative suspension is produced by the subjecting a fluorocarbon to certain stressors, such as oxidizing agents, reactive intermediates, physiological gases, benzo-?-pyrone derivatives, ultrasonic-cavitation, electric fields, magnetic fields, UV radiation, active metal catalyst, surfactant reactants, buffers, electrolytes, glucose, glucose derivatives, for the purpose of inducing a cascading immune response.
    Type: Application
    Filed: August 13, 2011
    Publication date: February 16, 2012
    Inventor: Demetrios Markou
  • Patent number: 8106097
    Abstract: The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like).
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: January 31, 2012
    Assignee: Genfit
    Inventors: Jamila Najib, Karine Caumont-Bertrand
  • Publication number: 20110263554
    Abstract: The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g. filovirus infections, as well as compositions having one or more agents to prevent, inhibit or treat viral infection.
    Type: Application
    Filed: November 6, 2009
    Publication date: October 27, 2011
    Applicant: WARF - Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Shinji Watanabe, Yasuko Hatta
  • Publication number: 20110135764
    Abstract: Embodiments of the invention relate to a composition for controlling a target pest, wherein the composition includes at least two active ingredients selected from the group consisting of thymyl acetate, linalyl acetate, amyl butyrate, anise star oil, black seed oil, p-cymene, geraniol, isopropyl myristate, d-limonene, linalool, lilac flower oil, methyl salicylate, alpha-pinene, piperonal, piperonyl alcohol, tetrahydrolinalool, thyme oil white, thyme oil red, thymol, vanillin, and winter-green oil, wherein the composition causes synergistic control of the target pest.
    Type: Application
    Filed: March 19, 2009
    Publication date: June 9, 2011
    Applicant: TyraTech, Inc.
    Inventor: Essam Enan
  • Patent number: 7943669
    Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: May 17, 2011
    Assignee: High Point Pharmaceuticals, LLC
    Inventor: Soren Ebdrup
  • Patent number: 7923473
    Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: April 12, 2011
    Assignee: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Remo Kranich, Anke S. Busemann
  • Patent number: 7919532
    Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: April 5, 2011
    Assignee: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Remo Kranich
  • Patent number: 7863287
    Abstract: The present invention is directed to a pharmaceutical composition and method for the treatment of rhinitis and cold-like symptoms which includes a non-steroidal anti-inflammatory drug (NSAID), a decongestant, and an antihistamine. It has been found that an NSAID enhances the activity of a decongestant and an anti-histamine, thus permitting a reduction in either or both in administration of separate dosage forms. The same enhancement can also occur with an anti-tussitive. Thus, the effective amount of the decongestant or the antihistamine or both is less than about 75% of an amount present in an approved dose of the decongestant or the antihistamine, or both, relative to an amount of the NSAID corresponding to about 100% of the amount present in a normal strength dosage form of the NSAID.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: January 4, 2011
    Assignee: Wyeth LLC
    Inventor: Roger G. Berlin
  • Publication number: 20100286589
    Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in blood vessels of a patient is provided. The chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive product is administered at sites of the plaques formed in the patient's blood vessels. The chemical composition comprises, for example, one or more of d-limonene, propylene glycol, octanic acid, 2-octane, and glycerine. The chemical composition enables modification of the plaques by altering composition of the plaques. The modification comprises partial dissolution, complete dissolution or elimination of the plaques. The modification makes the plaques amenable to different forms of plaque treatment, for example, balloon angioplasty, stenting, atherectomy, etc. The modified plaques are eliminated from the body of the patient.
    Type: Application
    Filed: May 4, 2010
    Publication date: November 11, 2010
    Inventor: Kusai Saadeldin Aziz
  • Publication number: 20100240768
    Abstract: The invention relates to a novel nutraceutical composition containing thymol and/or p-cymene, or a plant extract containing thymol or p-cymene as active ingredient(s). The compositions are useful for improvement of cognitive functions and psycho-social status, such as learning, memory and alertness, psychotic stability and maintenance.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 23, 2010
    Inventors: Ann Fowler, Regina Goralczyk, Claus Kilpert, Annis Mayne-Mechan, Hasan Mohajeri, Bernd Mussler, Adrian Wyss
  • Patent number: 7723385
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: May 25, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
  • Patent number: 7658939
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: February 9, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20100028317
    Abstract: Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace.
    Type: Application
    Filed: June 23, 2009
    Publication date: February 4, 2010
    Inventors: Daniel H. Maes, Nadine A. Pernodet, Thomas Mammone, Edward Pelle, Donald F. Collins, Lenny Slutsky, Kerri Goldgraben, James Timothy McCarthy
  • Patent number: 7632870
    Abstract: The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like).
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: December 15, 2009
    Assignee: Genfit
    Inventors: Jamila Najib, Karine Caumont-Bertrand